Last reviewed · How we verify
Intra-articular injection of ADMSC
Intra-articular injection of ADMSC is a Biologic drug developed by Medical University of Warsaw. It is currently in Phase 1 development.
At a glance
| Generic name | Intra-articular injection of ADMSC |
|---|---|
| Sponsor | Medical University of Warsaw |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients. (NA)
- Adipose-derived Mesenchymal Stem Cells in Osteoarthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra-articular injection of ADMSC CI brief — competitive landscape report
- Intra-articular injection of ADMSC updates RSS · CI watch RSS
- Medical University of Warsaw portfolio CI
Frequently asked questions about Intra-articular injection of ADMSC
What is Intra-articular injection of ADMSC?
Intra-articular injection of ADMSC is a Biologic drug developed by Medical University of Warsaw.
Who makes Intra-articular injection of ADMSC?
Intra-articular injection of ADMSC is developed by Medical University of Warsaw (see full Medical University of Warsaw pipeline at /company/medical-university-of-warsaw).
What development phase is Intra-articular injection of ADMSC in?
Intra-articular injection of ADMSC is in Phase 1.